A longish segment on Sky News which you'd think must help it tomorrow. They emphasised the link with the Burnet institute and the fact that they are ready to capitalise on the research of the last number of years (Select have a priority on developing these) and the fact that the hepatitis diagnostic kits will be sold in first and third world countries. They also said taht they could have issued 3 times the number of shares in the startup but that they wanted to keep the cap down at this stage. That cap is the important thing for me. Even now it's only around $10 million. Most of the biotechs around have alt least 100 million shares on issue. At 25% of this SLT could go to $1.00 and only have a cap of $25million.
I hold SLT. Do your own research before investing.
SLT Price at posting:
0.0¢ Sentiment: None Disclosure: Held